[go: up one dir, main page]

CY1108011T1 - Συνδυασμος παρεμποδιστου nsaid και pde4 - Google Patents

Συνδυασμος παρεμποδιστου nsaid και pde4

Info

Publication number
CY1108011T1
CY1108011T1 CY20071100595T CY071100595T CY1108011T1 CY 1108011 T1 CY1108011 T1 CY 1108011T1 CY 20071100595 T CY20071100595 T CY 20071100595T CY 071100595 T CY071100595 T CY 071100595T CY 1108011 T1 CY1108011 T1 CY 1108011T1
Authority
CY
Cyprus
Prior art keywords
nsaid
pde4 inhibitor
inhibitor combination
nsaids
inflammatory diseases
Prior art date
Application number
CY20071100595T
Other languages
English (en)
Inventor
Thomas Klein
Hans-Peter Kley
Armin Hatzelmann
Manfrid Eltze
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of CY1108011T1 publication Critical patent/CY1108011T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεσις αφορά τον συνδυασμό χορηγήσεως παρεμποδιστών PDE4 και NSAIDs δια την θεραπευτική αγωγή φλογιστικών ασθενειών και/ή παθήσεων που συνδυάζονται με φλόγωσιν, υπό περιορισμόν εις το ελάχιστον των γαστροεντερικων παρενεργειών όπως γαστρικές διαβρώσεις και έλκη τα οποία συνδυάζονται συχνά με τη χρησιμοποίηση NSAIDs.
CY20071100595T 2001-09-19 2007-05-07 Συνδυασμος παρεμποδιστου nsaid και pde4 CY1108011T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000473 2001-09-19
EP02772313A EP1429807B1 (en) 2001-09-19 2002-09-17 Combination of a nsaid and a pde-4 inhibitor

Publications (1)

Publication Number Publication Date
CY1108011T1 true CY1108011T1 (el) 2013-09-04

Family

ID=8176065

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100595T CY1108011T1 (el) 2001-09-19 2007-05-07 Συνδυασμος παρεμποδιστου nsaid και pde4

Country Status (24)

Country Link
US (2) US20040242597A1 (el)
EP (1) EP1429807B1 (el)
JP (1) JP4588998B2 (el)
KR (1) KR100949528B1 (el)
CN (1) CN100496607C (el)
AT (1) ATE355080T1 (el)
AU (1) AU2002337105B2 (el)
BR (1) BR0212606A (el)
CA (1) CA2459757C (el)
CY (1) CY1108011T1 (el)
DE (1) DE60218497T2 (el)
DK (1) DK1429807T3 (el)
EA (1) EA008108B1 (el)
ES (1) ES2282469T3 (el)
HU (1) HU229442B1 (el)
IL (2) IL160271A0 (el)
MX (1) MXPA04002562A (el)
NO (1) NO331756B1 (el)
NZ (1) NZ532278A (el)
PL (1) PL210463B1 (el)
PT (1) PT1429807E (el)
SI (1) SI1429807T1 (el)
WO (1) WO2003024489A2 (el)
ZA (1) ZA200402654B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110424A1 (en) * 2003-05-28 2004-12-23 Glaxo Group Limited Method and pharmaceutical formulation for reducing stress-induced accelerated colonic transit in a mammal
US20050059741A1 (en) * 2003-08-07 2005-03-17 B.M.R.A. Corporation B.V. Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-1
BRPI0415753A (pt) * 2003-10-21 2006-12-19 Pharmacia Corp método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
EP1683521A1 (en) * 2005-01-21 2006-07-26 Centre National De La Recherche Scientifique (Cnrs) Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same
EP1688413A1 (en) * 2005-02-03 2006-08-09 Hikma Pharmaceuticals Co. Ltd. Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases
EP1865951A1 (en) * 2005-03-14 2007-12-19 Nycomed GmbH Method for preventing cardiovascular diseases
JP2008543806A (ja) * 2005-06-17 2008-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療のためのｍｒｐｉｖインヒビター
CN102671195B (zh) * 2006-04-28 2016-01-20 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
FR2909876A1 (fr) * 2006-12-19 2008-06-20 Galderma Res & Dev S N C Snc Utilisation du nepafenac ou ses derives pour le traitement de desordres dermatologiques
AU2009206368B2 (en) 2008-01-25 2014-12-11 Vtv Therapeutics Llc Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
WO2009109908A1 (en) * 2008-03-04 2009-09-11 Pfizer Limited Methods of treating inflammatory pain
WO2010097334A1 (de) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
CA2753597A1 (en) 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Drug combinations containing pde4-inhibitors and nsaids
MD20150071A2 (ro) 2013-02-19 2016-02-29 Pfizer Inc. Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
HUE044040T2 (hu) 2014-08-06 2019-09-30 Pfizer Imidazopiridazin vegyületek
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20230017266A1 (en) * 2019-12-03 2023-01-19 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cyclooxygenase-2 Inhibition for the Treatment of SAA-high Asthma
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
IL304924A (en) 2021-02-10 2023-10-01 Iolyx Therapeutics Inc Methods for ophthalmic delivery of roflumilast
WO2023049809A1 (en) * 2021-09-22 2023-03-30 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
GB2228736A (en) 1989-02-10 1990-09-05 Sterivet Lab Ltd Cosmetic formulation
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
AU754734B2 (en) 1997-11-04 2002-11-21 Pfizer Products Inc. Indazole bioisostere replacement of catechol in therapeutically active compounds
NZ515711A (en) 1999-06-24 2004-01-30 Pharmacia Corp Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation
TR200909479T2 (tr) * 1999-08-21 2012-02-21 Nycomed Gmbh Sinerjistik kombinasyon.
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
ECSP003747A (es) * 1999-11-02 2002-05-23 Smithkline Beecham Corp Metodo y composiciones para el tratamiento de las enfermedades pulmonares
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6372777B1 (en) * 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
BR0107964A (pt) * 2000-01-31 2002-10-29 Pfizer Prod Inc Derivados de nicotinamida benzofundida com heterociclica úteis como inibidores seletivos de isozimas pde4
CZ20022682A3 (cs) * 2000-02-08 2003-09-17 Smithkline Beecham Corporation Farmaceutické kompozice pro léčení zánětlivého onemocnění
EA200300652A1 (ru) * 2001-01-31 2003-12-25 Пфайзер Продактс Инк. Эфирные производные, полезные в качестве ингибиторов изозимов pde4
JP4301812B2 (ja) * 2001-02-15 2009-07-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしてのフタラインオン−ピペリジノ−誘導体

Also Published As

Publication number Publication date
WO2003024489A2 (en) 2003-03-27
NO20041596L (no) 2004-06-18
CA2459757C (en) 2011-08-30
ES2282469T3 (es) 2007-10-16
US20040242597A1 (en) 2004-12-02
CN1625411A (zh) 2005-06-08
WO2003024489A3 (en) 2003-09-18
NZ532278A (en) 2006-02-24
ZA200402654B (en) 2005-04-26
IL160271A (en) 2008-03-20
HUP0401582A2 (hu) 2004-11-29
NO331756B1 (no) 2012-03-19
HU229442B1 (hu) 2013-12-30
DE60218497T2 (de) 2007-11-08
IL160271A0 (en) 2004-07-25
EP1429807B1 (en) 2007-02-28
US8242146B2 (en) 2012-08-14
CN100496607C (zh) 2009-06-10
HK1066730A1 (en) 2005-04-01
DK1429807T3 (da) 2007-06-18
US20080255209A1 (en) 2008-10-16
AU2002337105B2 (en) 2008-03-20
SI1429807T1 (sl) 2007-08-31
ATE355080T1 (de) 2006-03-15
PL369472A1 (en) 2005-04-18
PT1429807E (pt) 2007-05-31
PL210463B1 (pl) 2012-01-31
JP4588998B2 (ja) 2010-12-01
KR20040053129A (ko) 2004-06-23
KR100949528B1 (ko) 2010-03-25
EA200400410A1 (ru) 2004-12-30
DE60218497D1 (de) 2007-04-12
HUP0401582A3 (en) 2008-04-28
CA2459757A1 (en) 2003-03-27
MXPA04002562A (es) 2004-05-31
EA008108B1 (ru) 2007-04-27
BR0212606A (pt) 2004-08-17
EP1429807A2 (en) 2004-06-23
JP2005504077A (ja) 2005-02-10

Similar Documents

Publication Publication Date Title
CY1108011T1 (el) Συνδυασμος παρεμποδιστου nsaid και pde4
CY1124931T1 (el) Αντιμετωπιση της φαινυλκετονουριας με bh4
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
CY1106357T1 (el) Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
CY1105586T1 (el) Ιμιδαζοκουινολινες υποκατεστημενες με θειοαιθερα
CY1105286T1 (el) Ω-καρβοξυαρυλυποκατεστημενες διφαινυλουριες σαν αναστολεις της raf κινασης
CY1113651T1 (el) Αντιφλεγμονωδη σκευασματα
CY1107285T1 (el) ΣΥΝΔΥΑΣΜΟΙ ΑΠΟΤΕΛΟΥΜΕΝΟΙ ΑΠΟ ΑΝΑΣΤΟΛΕΙΣ cGMP PDE5
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
CY1110954T1 (el) Ημιστερεες βλεννοκολλωδεις φαρμακοτεχνικες μορφες
CY1119343T1 (el) Μεθοδοι για θεραπεια καταστασεων που συνδυαζονται με εξαρτωμενη απο masp-2 ενεργοποιηση συμπληρωματος
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
CY1106598T1 (el) Παραγωγα κινολινης και ισοκινολινης, μεθοδος για την παραγωγη αυτων και χρηση αυτων ως αντιφλεγμονωδη μεσα
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
DE60124256D1 (de) Aspirin-ausgelöste lipidmediatoren
TR200103575T2 (tr) Sülfonamid ve sülfamid ikameli/katkılı imidazokinolinler
CY1111902T1 (el) Χρηση ακυλοφωσφοχολινων σε συνδυασμο με αντινεοπλασματικα φαρμακα
CY1114468T1 (el) Ροφλουμιλαστη για τη θεραπεια της πνευμονικης υπερτασης
CY1109992T1 (el) Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
CY1116384T1 (el) Παραγωγα σουλφαμιδιου ως αναστολεις tafia
DK1313740T3 (da) Prodrugs af imidazopyridinderivater
CY1105429T1 (el) Φαρμακευτικη συνθεση συνδυαζουσα τενατοπραζολη και ενα αντιφλεγμονωδες
BRPI0416680A (pt) inibidores da forma mutante de kit
SE9802793D0 (sv) New compounds